Progyny (NASDAQ:PGNY) Releases Q2 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) updated its second quarter 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.500-0.53 for the period, compared to the consensus estimate of 0.440. The company issued revenue guidance of $342.0 million-$355.0 million, compared to the consensus revenue estimate of $349.5 million. Progyny also updated its FY 2026 guidance to 1.980-2.09 EPS.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Progyny in a research note on Friday, March 27th. Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Thursday. KeyCorp reduced their price target on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. BTIG Research reduced their price target on shares of Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. Finally, Citigroup raised shares of Progyny to an “outperform” rating in a research report on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Progyny has an average rating of “Moderate Buy” and an average target price of $27.91.

Progyny Stock Up 23.8%

Shares of PGNY stock opened at $23.72 on Friday. Progyny has a 12 month low of $16.10 and a 12 month high of $28.75. The business’s 50 day moving average is $17.87 and its two-hundred day moving average is $21.69. The company has a market cap of $1.86 billion, a PE ratio of 30.81, a price-to-earnings-growth ratio of 1.10 and a beta of 0.91.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.26 by $0.03. Progyny had a return on equity of 12.76% and a net margin of 5.23%.The company had revenue of $328.50 million for the quarter, compared to the consensus estimate of $326.47 million. During the same quarter last year, the company posted $0.17 earnings per share. The company’s revenue for the quarter was down 26.4% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, equities analysts expect that Progyny will post 1.12 EPS for the current fiscal year.

Insider Buying and Selling

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total transaction of $81,031.80. Following the transaction, the executive vice president owned 89,879 shares in the company, valued at $1,563,894.60. This trade represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 7,455 shares of company stock worth $129,515 in the last 90 days. Company insiders own 9.90% of the company’s stock.

Progyny News Summary

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny beat Q1 estimates, reporting $0.50 adjusted EPS versus $0.44 expected and revenue of $328.5 million versus $326.5 million forecast, helping reinforce the stock’s move higher. Progyny, Inc. Announces First Quarter 2026 Results
• Positive Sentiment: The company raised second-quarter and full-year 2026 guidance, with Q2 EPS outlook of $0.50 to $0.53 and FY2026 EPS guidance of $1.98 to $2.09, both above Wall Street estimates, which supports confidence in future earnings power. Conference call and earnings materials
• Positive Sentiment: Management said early selling-season activity and member engagement were strong, and the company highlighted continued share repurchases, with 8.8 million shares bought back since November, adding another supportive signal for investors. Progyny, Inc. Announces First Quarter 2026 Results
• Neutral Sentiment: Revenue was still down 26.4% year over year, so while the quarter beat expectations, investors may remain focused on whether growth can stabilize after the recent decline. Progyny: Q1 Earnings Snapshot
• Neutral Sentiment: Some commentary noted concern around flat revenue guidance, which could temper the bullish reaction if investors want clearer top-line acceleration going forward. The Bull Case For Progyny (PGNY) Could Change Following Flat Q1 2026 Revenue Guidance Concerns

Institutional Investors Weigh In On Progyny

Several hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp grew its stake in shares of Progyny by 1.5% in the fourth quarter. State Street Corp now owns 2,953,186 shares of the company’s stock worth $75,838,000 after acquiring an additional 44,642 shares during the last quarter. Wellington Management Group LLP boosted its stake in Progyny by 260.9% during the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock worth $57,607,000 after buying an additional 1,621,688 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after buying an additional 545,431 shares in the last quarter. Geode Capital Management LLC boosted its stake in Progyny by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock worth $50,655,000 after buying an additional 20,533 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Progyny by 12.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,712,039 shares of the company’s stock worth $43,966,000 after buying an additional 184,679 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.